

June 14, 2016  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

**Onconova Announces Presentation of Clinical Data from Oral  
Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic  
Syndromes at EHA Annual Meeting**

TOKYO, Japan, June 14, 2016 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, “Onconova”) announced on June 13, 2016 (EST) the presentation of interim data by U.S. and European Onconova collaborators from the ongoing fully-enrolled Phase 2 clinical trial of oral rigosertib/azacitidine combination in patients with either first- or second-line higher-risk myelodysplastic syndromes at the annual European Hematology Association (EHA) meeting in Denmark, which took place June 9 – 11, 2016.

Onconova is finalizing such results to initiate the end of Phase 2 trial discussions with U.S. and European regulatory agencies to define the next steps in the development plan for this combination therapy.

SymBio obtained the licensing rights for rigosertib in July, 2011 and retains the development rights for Japan and Korea.

For more details in this press release, please visit Onconova’s homepage at <http://investor.onconova.com/releases.cfm>

This event will not impact the Company’s current financial forecast.

**[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125

### **About Myelodysplastic Syndromes (MDS)**

MDS patients often require frequent blood transfusions due to the development of severe anemia (decrease in the number of red blood cells), with a high rate of progression to acute myelogenous leukemia (AML). There are an estimated 11,000 MDS patients in Japan alone, with the number of cases expected to increase as the population ages. MDS and AML are widely recognized as two blood disorders that are difficult to manage given the limited therapeutic options available for patients, particularly for patients who have a drug-resistant form of the disease. A high unmet medical need clearly exists for the establishment of new effective therapies to treat both lower-risk MDS and higher-risk MDS.

### **About Onconova Therapeutics, Inc.**

Onconova Therapeutics is a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages.

For more information, please visit <http://www.onconova.com>.

### **About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the United States, called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, USA, President: Mr. Fuminori Yoshida).

The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.